Opthea Limited - Eyeing the Global Opportunity in Retinal Diseases
Opthea Limited Eyeing the global opportunity in retinal diseases Opthea Ltd (ASX:OPT) is a clinical-stage biotechnology company focused on...
966 Views
Index Rebalance & ETF Flow Recap: HSI, HSCEI, HSTECH, HSCI, S&P/ASX, SET50, LIC, SBI Sumishin, Crown
This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...
647 Views
Paradigm Biopharmaceuticals (PAR AU): Concerns on First Potentially Commercialized Product
The company's dependence on a single molecule makes it a risky bet. Moreover, the inherent safety concern of the lead candidate may limit its...
432 Views
ASX100/​200/300 Index Rebalance Preview (March 2022): A Lot Happening From Now to March
There will be many changes to the ASX100/200/300 indices from now to March due to M&A activity & price moves. Plus a large funding trade following...
1.1k Views
Taxing Times For Australia
The Government's release of Re:think, its tax discussion paper, is a welcome development, designed to kick-start the conversation with the...
6k Views